{"name":"Biosion, Inc.","slug":"biosion-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BSI-045B","genericName":"BSI-045B","slug":"bsi-045b","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BSI-045B","genericName":"BSI-045B","slug":"bsi-045b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"trial","source":"The Manila Times","summary":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - The Manila Times","headline":"Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPNTlrMzJLMTUyX3RKRzJWYi1UX1RvSlZ2RUNEd2EtcDJmemhHLUlFZXQxSjcza29rTE9kUFRwRUN2ckdQS0tMcHhfUEN1VDUxeHZMQ1A4NWtqeUYwSFBpM1Y5ZUo3U1NqSk9nM2NtQXBwMDg0R2k3a2U4VTVkSktvR1pxVW8zdS1pQUZ5aExHU3dtY3Y3MTUyVmt2NzVITFBQUktxdHVORlM5WDFTcGZGYkJvM3pNc1ByYTFQT1ZNOUZBYkp6elFBbzNqT3RUQXBNU0FVYWoyemFGRUdUajJjTzlZX2kxX0phc1d2M0xoa1g5TWtvT1N0NVBWY2pZcERNd3N2ck5UV3FWU0MxUWtCbnd3?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire UK","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire UK","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9JbGdnSWVZT2I4VmlaY3dTUzdGN3hmV1A1V2ExTkVBdGxoOEY1dEx4SVNrWGVLajRiMkZXelh4LUdWampJcEpwdExGVWpxbng2elNUcWFEbmFUUDdJVHExU2V5T2dkcVpCZVpZdXZXNjUxRUpwLThMeTBwaTNTQjg?oc=5","date":"2025-09-02","type":"trial","source":"Yahoo Finance","summary":"OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors - Yahoo Finance","headline":"OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5DTHNFbTBNbi0zTW9acV9RczZfVUVSa2U5dnRKYzlUN21rZjFzUlRHZnBFS3o3OTEwNFllZmhGTWJDYk9ORWRyVVRrcF9KeFpqZlpDMkFxaV9WOU80endMQkZsZ2VqS090Tm9zUXlndDBSamRMcVlvU1Vn?oc=5","date":"2024-11-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"Aclaris Therapeutics secures global rights to Biosion’s antibodies - Pharmaceutical Technology","headline":"Aclaris Therapeutics secures global rights to Biosion’s antibodies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNVElyc3ZWeGVudjhVaDhmN3g3c0JoMU85WHR0bDJIVUJVc1VzeDRZRGFleFRoVElzQUxGNVNVSkR0NnUxZkdaUXFHLVBYUU5KNVk2X215WFBwZXRoX1hKUXZTUHVodnYwa2xjOWJaQ1ZsUlRUbGZIVlRQQXdHcEt2ZllXY0lPZHlrdnJvbVg0MGt4LVJNa2JGSllNRmNJcXBvcVlROUx3NFppZDVVRzM3aGY2MU42eGJuZjRpLS1sREJiZDlxTmhfamdDYS11bm9TNldpNnNKU1dBTWNIX0dxZC1iR0c?oc=5","date":"2024-11-19","type":"deal","source":"BioPharma APAC","summary":"Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M - BioPharma APAC","headline":"Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQbWMzRHJHTDhRZGJ6T1ZxZFBBa3lFR093c01BWEdXaDBTM1ZvcjhiN0lmMUNXSnBBclUzRkk5aXRrdDlrNFpqQVJWemd6M2ZvWjdYNmtlSVMzMHUyRjE5aEt3eTdOU2huZ2QwVnA3YkFCSnVEeEFXUi1vUmZLYm8yS1lkT3BLcjRFejFLcGstSGlSdGFIWkJwVzVrUnVTcmlkQktUNFphdVBFeEN6d1VWWUV4QkY3RC1pV01oRHpEVTNDN1lsOUpJSDVEdk5xMS00ZlM3aG54NGJxM3RQZWNPMkM1a2t4Yi04Qjc5Q0JiMEpDbEFHNEd6Y3lWa294Q3dfckN6NkxDa1VlZXBYWXo4UWJtZEtOdlVxN3JuYzZUSlZINzlfTzAzRFpHNUxkTjI3VnFtV1hhdmtidw?oc=5","date":"2024-11-18","type":"deal","source":"globenewswire.com","summary":"Aclaris Therapeutics Announces Exclusive, Global License - globenewswire.com","headline":"Aclaris Therapeutics Announces Exclusive, Global License","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNQjJqRF9ycFhIcWdEcDlfbmJqUnZSMG83R1VyOHliSkZnMTRnQ3RoYzlMTUFBOEJLUmpKSXd5dUVVaWI0MGM0Z1ByTkF0SHVVY3hwb0I4eEZQNVlBb1ZjOVVUbmxQOWpLS1VRanM3WHV1N19fNWYxRXppdUhaX2hqdEZMY2hSSDJmNmtnU1kwN05HMDc5OEc3R1pHSV9Gbm91amdOY1FJS2ZlbjRoeEh0aHByNHk0bHpRTjBaX1NSMWFrMUVRU0VxMm1tc2FTd0RvWmk5UWptcDRpWUFoaGZzUGVtXzFtYjlrTDA0a2ZscTNtb295TUpRSVotdXlwVW1tZDh5bmtsQVhoNHl3YkJ3MENHYVU2ZlNfaUhOSlNmS1g?oc=5","date":"2024-06-12","type":"trial","source":"globenewswire.com","summary":"OBI Pharma Announces Phase 1/2 Study Initiation for - globenewswire.com","headline":"OBI Pharma Announces Phase 1/2 Study Initiation for","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}